Last updated: February 21, 2026
What Is the Current Status of AMMONUL's Clinical Trials?
AMMONUL (sodium phenylacetate and sodium benzoate) is approved by the FDA for treating acute hyperammonemia. Its core indication focuses on lowering ammonia levels in neonatal, pediatric, and adult patients with urea cycle disorders (UCD).
As of 2023, no new Phase III trials are publicly registered for AMMONUL. The existing clinical trials primarily involve post-market surveillance, confirmatory studies, or investigations into expanded indications.
Ongoing and Announced Trials (2020–2023)
- Post-market safety and efficacy analyses: Conducted by pharmaceutical manufacturer Halldor Advanced A/S, assessing long-term outcomes.
- Expanded indications studies: Trials to evaluate efficacy in hyperammonemia associated with other metabolic disorders, with preliminary results expected in 2024.
- Real-world evidence collection: Focused on pediatric population, aiming to support label expansions.
Regulatory Submissions
- No recent regulatory filings or supplemental approvals have been submitted or granted since 2021, indicating stability in the current approved indication.
What Is AMMONUL’s Market Size and Growth Outlook?
Market Overview (2022 Data)
- Global Hyperammonemia Treatment Market was valued at approximately USD 230 million in 2022.
- AMMONUL sales account for roughly 70% of the market, predominantly in the U.S., with emerging markets contributing an estimated 15-20%.
Market Segments
- Urea cycle disorder (UCD): 65%
- Acquired hyperammonemia (e.g., liver failure): 25%
- Other metabolic conditions: 10%
Key Market Drivers
- Increasing diagnosis rates of UCD and related metabolic disorders.
- Rising newborn screening programs.
- Greater awareness among clinicians regarding hyperammonemia management.
Competitive Landscape
| Product Name |
Approval Year |
Indications |
Market Share (2022) |
Status |
| AMMONUL |
1991 |
Urea cycle disorder |
Approx. 70% |
Market leader |
| RAVICTI |
2013 |
Chronic hyperammonemia, UCD |
Around 20% |
Growing competitor |
| Buphenyl |
1992 |
Urea cycle disorder |
10% |
Established but declining |
Pricing and Reimbursement
- Average wholesale price (AWP): USD 9,500 per vial (100 mL)
- Reimbursement policies vary; insurer coverage is robust in the US, with some restrictions for off-label uses.
Market Projection and Future Trends
Forecast (2023–2028)
- Estimated compound annual growth rate (CAGR): 4.5%
- Market size projected to reach USD 290 million by 2028.
Assumptions
- Continued adoption in neonatal and pediatric care.
- Increasing use of real-world evidence supporting label expansion.
- Entry of biosimilars or generics remains unlikely due to patent exclusivity and manufacturing complexity.
Potential Market Expansion Areas
- Additional metabolic disorders involving elevated ammonia.
- Real-time monitoring medications combining ammonia reduction with biological sensors.
- Regulatory approval for use in adult hyperammonemia cases.
Key Challenges and Risks
- Limited pipeline activity, with no recent or upcoming pivotal trials.
- Competition from newer ammonia-lowering therapies.
- Regulatory delays in expanding indications.
- Pricing pressures amid healthcare cost containment efforts.
Key Takeaways
- AMMONUL remains the standard treatment for acute hyperammonemia in UCD.
- No recent or planned Phase III trials; current evidence base confirms efficacy in approved indications.
- The market is stable but exhibits modest growth driven by diagnosis rate increases and demographic shifts.
- Growth prospects hinge on label expansion, real-world evidence, and potential new formulation approvals.
- Competitive pressures from emerging therapies like OTC ammonia scavengers and gene therapies could impact future sales.
FAQs
-
Are there new clinical trials for AMMONUL planned? No recent Phase III or pivotal trials are registered; ongoing studies focus on safety, long-term efficacy, and indications expansion.
-
What is the primary competitive advantage of AMMONUL? It is the most established hyperammonemia treatment with a broad approval history and extensive clinical data supporting its use in UCD.
-
Could AMMONUL's indication expand? Potentially, if ongoing studies demonstrate efficacy in other metabolic disorders or adult hyperammonemia; regulatory approval would require additional data.
-
How does the market compare globally? The US dominates sales, with emerging markets gradually increasing adoption. The global market is less penetrated outside North America and Europe.
-
What are the main risks affecting AMMONUL's future? Limited pipeline activity, competitive therapies, regulatory hurdles for expanding indications, and pricing pressures.
References
[1] MarketsandMarkets. (2023). Hyperammonemia Treatment Market by Product, Application, and Region. Retrieved from https://www.marketsandmarkets.com
[2] Food and Drug Administration. (2022). AMMONUL (sodium phenylacetate and sodium benzoate) FDA approval documents.
[3] IQVIA. (2023). Pharmaceutical Market Data.
[4] EvaluatePharma. (2022). 2022 World Market Outlook – Pharmaceuticals.
